UMB ICTR KL2 Scholar receives grant from the FDA to study opioid use disorder treatment patterns.
While the nation is undergoing unprecedent pandemic and opioid crises, Internal KL2 Scholars from UMB’s Institute of Clinical Translational Research (ICTR) are thriving and meeting these healthcare challenges.
Dr. Danya Qato, an assistant professor and a 2019 ICTR Internal KL2 scholar from School of Pharmacy, recently received a grant from the Food and Drug Administration (FDA) to study opioid use disorder treatment patterns. The grant ($797,513 over 2 years) is titled “Data-informed Models to Identify Optimal Opioid Use Disorder Treatment Trajectories.”
Dr. Qato and her colleagues will utilize longitudinal data from the publicly insured and commercially insured adult population to characterize temporal patterns of treatment modalities and examine the differential impact of temporal patterns of treatment modalities on critical health outcomes.